Nasdaq Aplm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq aplm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Aplm Today - Breaking & Trending Today

Apollomics (NASDAQ:APLM) Price Target Lowered to $5.00 at HC Wainwright

Apollomics (NASDAQ:APLM – Free Report) had its target price lowered by HC Wainwright from $17.00 to $5.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Apollomics’ Q1 2024 earnings at ($0.17) EPS, Q2 2024 earnings at ($0.18) EPS, […] ....

Geode Capital Management , Blackrock Inc , Apollomics Inc , Citadel Advisors , Apollomics Company Profile , Free Report , Get Free Report , Apollomics Daily , Nasdaq Aplm , Lower Price Target , Hc Wainwright ,

Apollomics to Present at the 2024 Biotech Showcase

FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company. ....

United States , San Francisco , Sanjeev Redkar , Sean Leous , Peter Vozzo , Apollomics Inc , Exchange Commission , Securities Exchange , Hilton San Francisco Union Square , Biotech Showcase , Bio Partnering , Securities Act , Securities Exchange Act , Annual Report , Nasdaq Aplm , Apollomics Inc ,

Apollomics Announces Presentation of Vebreltinib Data at

FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company. ....

United States , Sean Leous , Peter Vozzo , Apollomics Inc , Exchange Commission , Avistone Biotechnology Co , National Medical Products Administration , Securities Exchange , America Conference , Lung Cancer , Without Concurrent , Distributions Compared With Public , Avistone Biotechnology , Securities Act , Securities Exchange Act , Nasdaq Aplm , Apollomics Inc ,

Apollomics (NASDAQ:APLM) Price Target Cut to $17.00

Apollomics (NASDAQ:APLM – Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $18.00 to $17.00 in a report released on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 431.25% from the company’s previous close. […] ....

United States , George Kaiser Family Foundation , Apollomics Inc , Geode Capital Management , Exchange Traded Concepts , Get Free Report , Kaiser Family Foundation , Traded Concepts , Capital Management , Clear Street , Apollomics Daily , Nasdaq Aplm , Lower Price Target , Hc Wainwright ,

Apollomics Reports First Half 2023 Financial Results and

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half. ....

United States , Guo Liang Yu , Peter Vozzo , Sean Leous , Exchange Commission , Maxpro Capital Acquisition Corp , Securities Exchange , Us National Cancer Institute , Apollomics Inc , China National Medical Products Administration , Chief Executive Officer , Drug Administration , Beijing Pearl , Breakthrough Therapy , Cancer Institute , Maxpro Capital Acquisition , Apollomic Class , Nasdaq Capital Market , Results Conference , Securities Act , Securities Exchange Act , Annual Report , Registration Statement , Nasdaq Aplm , Apollomics Inc ,